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a b s t r a c t
Fanconi anemia (FA) is a genetic disorder of chromosomal instability. One of the routine
methods of confirmation for FA includes chromosome breakage analysis, using cros-
slink-inducing agents. Bone marrow karyotyping at diagnosis and further follow-up will
aid in detecting aberrations. If present, they might be indicative of a possible karyotype
evolution, leading to poor prognosis. We report a FA patient with two distinct karyoty-
pes: 46,XY,dup(1)(q21q31) in the first diagnostic sample and 46,XY,dup(1)(q21q31),der
(13)t(3;13)(?q26;p12) in the second, after a span of two years. We discuss the possible
karyotypic evolution, the implications of chromosome 13 involvement and regions/
genes on chromosomes 1q and 3q in FA. The importance of periodic examination of
bone marrow in these patients, for detection of cryptic aberrations which might lead
them to MDS/AML, is also discussed.
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Fanconi anemia (FA) is a chromosome instability syndrome
with progressive bone marrow (BM) failure and increased
risk of cancers. Karyotyping of BM, forms an essential
investigation at diagnosis, prior to bone marrow transplan-
tation (BMT). Periodic karyotyping is beneficial, besides* Corresponding author at: Cytogenetics Unit, Department of Geneti
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z o.o. All rights reserved.testing for breakage scoring alone, which is one of the
confirmatory methods to differentiate between FA and
aplastic anemia. Clinical observation showed that detect-
ability of chromosomal aberrations in BM aspirates of FA
patients can vary over time, with clones becoming transi-
ently undetectable. This has led to underestimation of
clinical relevance of chromosomal aberrations in FA [1].
Better clinical relevance and biological implications ofcs, P.O. Box: 35, College of Medicine & Health Sciences, Sultan
w, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp.
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case series by advanced molecular cytogenetic technologies
along with conventional karyotyping [2–5]. Clonal evolution
and associated chromosomal aberrations in FA are impor-
tant for understanding malignant transformation mechan-
isms; therefore, they had wider implications. That led to the
identification and delineation of a specific pattern of chro-
mosomal aberrations in FA, characteristically unbalanced,
with gain/loss of chromosomal material during clonal evolu-
tions. We report a patient who developed secondary addi-
tional chromosome abnormalities 2 years after the initial
diagnosis, and thus indicating possible karyotypic evolution.
The possible implications are discussed.
Patient details
A 22-year-old male patient was admitted with febrile
episodes and diarrhea. Clinical examination indicated dys-
morphic features; deformities of the chest wall, with grade
one clubbing and scar from previous surgeries, and abnor-
mal thumbs, hands and abnormally placed ears. Ultrasound
investigation revealed abnormal kidneys. He was also oper-
ated earlier for esophageal atresia and cardiac lesions and
labeled VATER syndrome (Vertebrae, Anus, Trachea, Esopha-
gus, Renal). His cognitive function was average. Peripheral
smear findings and bone marrow aspiration (BMA) exhibited
dysplasia. The family history indicated that the patient had
a brother with FA who died 15 years back, after it
transformed to AML.
Methods, results and discussion
Breakage scoring on peripheral blood using caryolysin
(0.05 mg/ml) showed chromosome breakage, chromatid
exchanges, and dicentric and triradial images, in 98% of
cells (controls 2%). A year later, a repeat also showed theFig. 1 – (a) Karyotype of bone marrow at diagnosis showing dup(1
up) bone marrow (2 years after the initial diagnosis), showing dsame rearrangements of breakage. These results were con-
sistent with the diagnosis of FA.
Karyotype on diagnostic bone marrow in 2012 showed
dup(1)(q21q31) (Fig. 1(a)) as a sole clonal abnormality. Two
years later, in 2014, a repeat cytogenetics showed persis-
tence of dup(1)(q21q31) with a secondary additional struc-
tural abnormality – add(13)(p12) (Fig. 1(b)). This indicated
a possible clonal karyotype evolution (transformation). Spec-
tral karyotyping (SKY) identified the additional abnormality
on 13p, as part of chromosome 3 and hence, the karyotype
was redefined as 46,XY,dup(1)(q21q31),der(13)t(3;13)(?q26;
p12)[18] (Fig. 2).
FA patients are known to have chromosomal aberration
in bone marrow, which might later transform to MDS or
AML. Partial duplications/triplications of chromosome 1q
have been documented [6–8]. The most frequently involved
region is 1q21 which harbors fragile sites and oncogenes
involved in AML [6]. Cells with chromosome triplication
are considered to have evolved from a previous duplication.
The duplication region in our patient was (1)(q21q31). The
consequence is a genomic amplification of a specific chro-
mosomal region. In one report, dup(1)(q21q42) was found in
the first sample and 7 months later when patient had
transformed to AML, the second sample showed del(1)(q32)
[9]. Our patient showed dup(1)(q21q31) on diagnostic sam-
ple, while a repeat after 2-years showed an additional
abnormality der(13)t(3;13). Clonal evolution observed in FA
after initial diagnosis is frequent gains of 1q and 3q,
characteristically unbalanced with gain and loss of chromo-
somal material [2–4, 10], as observed in our patient, with the
occurrence of der(13)t(3;13). 3q gain is a particular character-
istic for FA and its clinical implications indicate transforma-
tion to MDS/AML and FA related myelodysplasia [2–4, 10].
Chromosomal aberrations, such as inversions or transloca-
tions involving the 3q, are well documented in myeloid
malignancies from non-FA patients, particularly adults [11,
12]. Gene expression resulting from FA-specific gain in 3q26-
3q29 has been studied to understand the important role of)(q21q31) as sole abnormality; (b) karyotype of repeat (follow-
up(1)(q21q31) (arrow) and an additional add(13)(p12)
Fig. 2 – Spectral karyotype showing add(13)(p12) as part of chromosome 3 (arrow heads)
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1) for leukemic transformation in FA [13, 14]. The EVII
(MECOM) gene analysis could not be performed in our
patient. Gain of 1q is often the sole finding in the early
stages of clonal evolution, as observed in our patient, which
can persist for years. It also occurs frequently with 3q gain
and other aberrations. An evolution of similar nature might
have occurred over a span of 2 years in our patient; hence
the additional aberration of 3q was observed. Tönnies et al.
[2] observed high incidence of 3q aberrations in FA patients,
with subtle aberrations due to unbalanced translocations of
distal 3q to various other chromosomes, including chromo-
some 13 as in our patient.
The evolution of karyotypic change after 2 years is
evidenced by the fact that 1q aberration was the diagnostic
observation which later evolved as t(3;13) in the form of der
(13)t(3;13). The characteristic clonal evolution of FA with
dominance of chromosomal gain and loss is at least likely
to be a specific result of the disruption of the FA/BRCA
pathway and partially caused by FA-related unresolved DNA
damage during S-phase [15, 16]. The striking overrepresenta-
tion of 1q and 3q could imply that these chromosomal
regions are particularly susceptible to FA/BRCA disruption-
associated damage.
Those with unbalanced translocation of a segment of
chromosome (3)(q26q29) leading to gain showed extremely
poor survival, compared to FA patients without such aberra-
tions [2]. Hence, routine FISH screening for 1q and 3q gain is
advisable for all FA-BM samples [4] which might help
determine patients at high risk. The ultimate goal is to detect
clonal abnormality and its involvement in the disease pro-
gression, which might facilitate the development of targeted
therapies in FA. The FA-characteristic 3q gain harbors leuke-
mogenic oncogenes, EVI1, first detected to be amplified andoverexpressed in FA-derived AML transformation in patients
with biallelic FANCD1/BRCA2 mutations [2, 3]. This suggests
that FA-associated leukemia shares its biology with one of
the most aggressive forms of sporadic AML [11, 12]. FISH
probes for break-apart EVII and RUNX1 might increase the
sensitivity of early detection of transformed cells.
Close monitoring for the presence and evolution of
chromosomal aberrations is essential in patients with BM
failures [14]. However, cytogenetic analysis should include
karyotyping and monitoring by FISH, for FA-characteristic
chromosomal aberrations. Techniques like aCGH and SKY
are valuable complementary tests, targeting FA-specific
chromosomal gain and loss [14]. Therefore, it is important
to investigate patients, by regular BM examination for these
chromosomal regions at diagnosis, later monitored for
karyotype evolution. Thus, patients at high risk can be
identified for a better management.
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